These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 33441425)
1. The intratumoral CXCR3 chemokine system is predictive of chemotherapy response in human bladder cancer. Vollmer T; Schlickeiser S; Amini L; Schulenberg S; Wendering DJ; Banday V; Jurisch A; Noster R; Kunkel D; Brindle NR; Savidis I; Akyüz L; Hecht J; Stervbo U; Roch T; Babel N; Reinke P; Winqvist O; Sherif A; Volk HD; Schmueck-Henneresse M Sci Transl Med; 2021 Jan; 13(576):. PubMed ID: 33441425 [TBL] [Abstract][Full Text] [Related]
2. Wrinkle in the plan: miR-34a-5p impacts chemokine signaling by modulating CXCL10/CXCL11/CXCR3-axis in CD4 Hart M; Nickl L; Walch-Rueckheim B; Krammes L; Rheinheimer S; Diener C; Taenzer T; Kehl T; Sester M; Lenhof HP; Keller A; Meese E J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33229509 [TBL] [Abstract][Full Text] [Related]
3. CXCR3 Ligands in Cancer and Autoimmunity, Chemoattraction of Effector T Cells, and Beyond. Karin N Front Immunol; 2020; 11():976. PubMed ID: 32547545 [TBL] [Abstract][Full Text] [Related]
4. The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD8+ T lymphocytes but not inhibition of angiogenesis. Hensbergen PJ; Wijnands PG; Schreurs MW; Scheper RJ; Willemze R; Tensen CP J Immunother; 2005; 28(4):343-51. PubMed ID: 16000952 [TBL] [Abstract][Full Text] [Related]
5. [Clinicopathological characteristics of the CD8 Chai X; Sun Z; Li H; Zhu L; Liu X; Liu Y; Pei F; Chang Q Beijing Da Xue Xue Bao Yi Xue Ban; 2024 Jun; 56(3):512-518. PubMed ID: 38864138 [TBL] [Abstract][Full Text] [Related]
6. Cross reactivity of three T cell attracting murine chemokines stimulating the CXC chemokine receptor CXCR3 and their induction in cultured cells and during allograft rejection. Meyer M; Hensbergen PJ; van der Raaij-Helmer EM; Brandacher G; Margreiter R; Heufler C; Koch F; Narumi S; Werner ER; Colvin R; Luster AD; Tensen CP; Werner-Felmayer G Eur J Immunol; 2001 Aug; 31(8):2521-7. PubMed ID: 11500837 [TBL] [Abstract][Full Text] [Related]
7. Intratumoral TIGIT Liu Z; Zhou Q; Wang Z; Zhang H; Zeng H; Huang Q; Chen Y; Jiang W; Lin Z; Qu Y; Xiong Y; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Xu L; Dai B; Guo J; Wang J; Chang Y; Zhang W J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32817209 [TBL] [Abstract][Full Text] [Related]
8. Enhancement of antigen-specific CD8 T cell responses by co-delivery of Fc-fused CXCL11. Namkoong H; Song MY; Seo YB; Choi DH; Kim SW; Im SJ; Sung YC; Park Y Vaccine; 2014 Feb; 32(10):1205-12. PubMed ID: 23928465 [TBL] [Abstract][Full Text] [Related]
9. Intratumoral IL22-producing cells define immunoevasive subtype muscle-invasive bladder cancer with poor prognosis and superior nivolumab responses. Zeng H; Liu Z; Wang Z; Zhou Q; Qi Y; Chen Y; Chen L; Zhang P; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Dai B; Guo J; Xu L; Zhang W; Xu J Int J Cancer; 2020 Jan; 146(2):542-552. PubMed ID: 31584197 [TBL] [Abstract][Full Text] [Related]
10. CXCL10 is the key ligand for CXCR3 on CD8+ effector T cells involved in immune surveillance of the lymphocytic choriomeningitis virus-infected central nervous system. Christensen JE; de Lemos C; Moos T; Christensen JP; Thomsen AR J Immunol; 2006 Apr; 176(7):4235-43. PubMed ID: 16547260 [TBL] [Abstract][Full Text] [Related]
11. Identification and validation of an excellent prognosis subtype of muscle-invasive bladder cancer patients with intratumoral CXCR5 Huang Q; Zhou Q; Zhang H; Liu Z; Zeng H; Chen Y; Qu Y; Xiong Y; Wang J; Chang Y; Xia Y; Wang Y; Liu L; Zhu Y; Xu L; Dai B; Guo J; Wang Z; Bai Q; Zhang W Oncoimmunology; 2020 Aug; 9(1):1810489. PubMed ID: 32939328 [TBL] [Abstract][Full Text] [Related]
12. Infiltrating CD8+ T cells in oral lichen planus predominantly express CCR5 and CXCR3 and carry respective chemokine ligands RANTES/CCL5 and IP-10/CXCL10 in their cytolytic granules: a potential self-recruiting mechanism. Iijima W; Ohtani H; Nakayama T; Sugawara Y; Sato E; Nagura H; Yoshie O; Sasano T Am J Pathol; 2003 Jul; 163(1):261-8. PubMed ID: 12819030 [TBL] [Abstract][Full Text] [Related]
13. Analysis of cysteine-X-cysteine motif chemokine ligands 9, 10, and 11, their receptor CXCR3, and their possible role on the recruitment of immune cells at the maternal-conceptus interface in pigs. Han J; Gu MJ; Yoo I; Choi Y; Jang H; Kim M; Yun CH; Ka H Biol Reprod; 2017 Jul; 97(1):69-80. PubMed ID: 28859287 [TBL] [Abstract][Full Text] [Related]
14. Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation. Flier J; Boorsma DM; van Beek PJ; Nieboer C; Stoof TJ; Willemze R; Tensen CP J Pathol; 2001 Aug; 194(4):398-405. PubMed ID: 11523046 [TBL] [Abstract][Full Text] [Related]
15. Small molecule chemokine mimetics suggest a molecular basis for the observation that CXCL10 and CXCL11 are allosteric ligands of CXCR3. Nedjai B; Li H; Stroke IL; Wise EL; Webb ML; Merritt JR; Henderson I; Klon AE; Cole AG; Horuk R; Vaidehi N; Pease JE Br J Pharmacol; 2012 Jun; 166(3):912-23. PubMed ID: 21895630 [TBL] [Abstract][Full Text] [Related]
19. Review: The chemokine receptor CXCR3 and its ligands CXCL9, CXCL10 and CXCL11 in neuroimmunity--a tale of conflict and conundrum. Müller M; Carter S; Hofer MJ; Campbell IL Neuropathol Appl Neurobiol; 2010 Aug; 36(5):368-87. PubMed ID: 20487305 [TBL] [Abstract][Full Text] [Related]
20. Interleukin-27 and IFNγ regulate the expression of CXCL9, CXCL10, and CXCL11 in hepatitis. Basset L; Chevalier S; Danger Y; Arshad MI; Piquet-Pellorce C; Gascan H; Samson M J Mol Med (Berl); 2015 Dec; 93(12):1355-67. PubMed ID: 26199110 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]